Vertex Pharmaceuticals is strutting toward its Q1 earnings report with a 22.3% stock surge this year, brushing up against its 52-week high. While analysts expect a dip in earnings per share, revenue ...

Simultaneously, these higher costs can lead to cuts in business investment and consumer spending, potentially slowing economic growth and leading to layoffs—the very definition of stagflation.

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Artificial Intelligence isn’t pushing IP boundaries anymore. It’s smashing them. The film and music industries are bracing ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

College of Mathematics and Statistics, Fujian Normal University, Fuzhou, Fujian 350117, P. R. China Center for Applied Mathematics of Fujian Province (Fujian Normal University), Fuzhou, Fujian 350117, ...

Over the past 15 years, Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products. CRISPR Therapeutics won its first regulatory ...

Leading industry experts join the Vertex Chief Strategy Office to shape product innovation and strengthen global compliance strategies for customers KING OF PRUSSIA, Pa., April 10, 2025 (GLOBE ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets had a difficult start to 2025; ...

SAN FRANCISCO--(BUSINESS WIRE)--Elastic (NYSE: ESTC), the Search AI Company, announced the general availability of the Elastic Google Cloud Vertex AI platform integration in Elastic Observability.

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.